Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gentafix 1 is a high viscosity, radiopaque, self-hardening bone cement containing gentamicin, an aminoglycoside antibiotic. It is dedicated to arthroplasty surgery—such as shoulder, hip, and knee procedures—and is used to provide immediate and stable anchorage of implants while delivering local antibiotic therapy to help cure or prevent infections. Gentamicin acts by binding to prokaryotic ribosomes, inhibiting protein synthesis in susceptible bacteria, and exhibiting a broad antibacterial spectrum against most bacteria encountered in orthopedic surgeries. The cement formulation enables optimized long-term release of gentamicin, reducing infection risk. Gentafix 1 is not a systemic pharmaceutical; it is a device-drug combination primarily for orthopaedic use. Developed and manufactured by Teknimed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gentafix 1.